Information Provided By: 
Fly News Breaks for August 13, 2019
CLSD
Aug 13, 2019 | 11:35 EDT
As previously reported, Laidlaw analyst Francois Brisebois downgraded Clearside Biomedical to Hold from Buy as he believes the company's decision to out-license their main product, Xipere, adds uncertainty for the foreseeable future in terms of topline growth. He lowered his price target on Clearside shares to $2 from $5, stating that he values CLS-TA for U.S. uveitis at $1.50 per share and the company's cash and technology at 50c per share.
News For CLSD From the Last 2 Days
There are no results for your query CLSD
